about
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinClinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy of chronic myeloid leukemia.
@en
Targeted therapy of chronic myeloid leukemia.
@nl
type
label
Targeted therapy of chronic myeloid leukemia.
@en
Targeted therapy of chronic myeloid leukemia.
@nl
prefLabel
Targeted therapy of chronic myeloid leukemia.
@en
Targeted therapy of chronic myeloid leukemia.
@nl
P2093
P2860
P1476
Targeted therapy of chronic myeloid leukemia.
@en
P2093
Con Sullivan
Dongguang Li
Shaoguang Li
Yaoyu Chen
P2860
P304
P356
10.1016/J.BCP.2010.05.001
P407
P577
2010-05-12T00:00:00Z